supervisory
supervisory with http://www.mdnewscast.net

supervisory

Medical Newscast

News for 14-Aug-25

Source: MedicineNet Diabetes General
Insulin Prices Skyrocket, Putting Many Diabetics in a Bind

Source: MedicineNet Diabetes General
Health Tip: Creating an Insulin Routine

Source: MedicineNet Diabetes General
Health Tip: Prepare for Travel With Diabetes

Source: MedicineNet Diabetes General
FDA OKs High-Tech Diabetes Device to Help Replace Fingerstick Tests

Source: MedicineNet High Blood Pressure General
Omega-3s a Recipe for Healthy Blood Pressure in Young Adults

Source: MedicineNet Diabetes General
glipizide and metformin (Metaglip has been discontinued in the US)

Source: MedicineNet Diabetes General
Can Protein, Probiotics Help With Blood Sugar Control?

Source: MedicineNet High Blood Pressure General
Sharp Drop in Blood Pressure After Rx May Be Risky for Some Heart Patients

Source: MedicineNet High Blood Pressure General
More Research Cites Salt's Potential Health Risks

Source: MedicineNet High Blood Pressure General
Even Small Rise in Blood Pressure Can Harm Black Patients

Search the Web
supervisory
management centre europe
achievement
american management assoc
accreditation
needs analysis
enterprise councils
rectorat
pendidikan
skills

The Best supervisory website

All the supervisory information you need to know about is right here. Presented and researched by http://www.mdnewscast.net. We've searched the information super highway far and wide to provide you with the best supervisory site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
supervisory.

supervisory

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

The links we have provided are secure. However when you purchase supervisory online ensure to print a copy of your purchase order and confirmation number for your records. We are confident that your supervisory purchase will be efficiently processed to your full satisfaction.

Our confidence is based on our own evaluation of the supervisory links that we have provided in this article. Enjoy your supervisory shopping and return regularly to explore the full range of all that is on offer.

supervisory

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

supervisory - Its such a common topic these days, and why? Well who knows why, the main thing is you want information about it. This website is dedicated to giving you the most information you need about supervisory.

Finding supervisory information from your home PC has never been easier and that's why we would like to share with you all the supervisory information that we have come up with so far.

Class of Drugs Brings Hope to Cancer Patients

 by: ARA Content

(ARA) - This is an exciting time in cancer research. Recent information on angiogenesis -- the growth of new blood vessels -- is providing researchers opportunities to find new ways to slow or stop a tumor's growth by cutting off the blood supply it needs.

Angiogenesis performs a critical role in the development of cancer. To grow, solid tumors need oxygen and nutrients provided by new blood vessels. Once a vascular network has been generated, cancer cells can also invade the rest of the body, a process called metastasis. Currently, researchers believe that more than 90 percent of all cancer cases are angiogenesis-dependent.

The good news is that a novel class of drugs, which acts as angiogenesis inhibitors, shows great potential in fighting more than 20 different diseases, including many types of cancer.

These "anti-angiogenesis" drugs being developed and tested block the formation of new blood vessels, starving cancerous cells and stopping tumor growth. One drug being tested, Neovastat, was discovered in 1994 and is derived from cartilage tissue. Neovastat is the only angiogenesis inhibitor being developed in the biotechnology and pharmaceutical universe that has four mechanisms of action to combat blood vessel growth. Furthermore, Neovastat is taken orally, making it convenient for patients who need long-term treatment, and it has shown minimal side effects in clinical trials. This means that unlike standard chemotherapy, Neovastat is not likely to interfere with a patient's immune system, or cause adverse gastrointestinal symptoms or hair loss.

In addition, because most cancer cells are genetically unstable and more prone to mutations, resistance is a major problem with many chemotherapy agents. But since anti-angiogenesis drugs target normal endothelial cells that are not genetically unstable, drug resistance is less likely to develop and has not been a problem so far in clinical trials.

Another hope is that angiogenesis inhibitors can be used in combination with therapies that directly target tumor cells. Because anti-angiogenic drugs and chemotherapy are aimed at different cellular targets, it is possible that the combination will prove even more effective than either therapy is as a stand-alone.

Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer for which there are urgent needs for new therapies. For multiple myeloma, the second most common form of blood cancer, the drug is in phase two trials with 125 patients in the United States, Canada and Europe. This trial should be completed by the end of 2002. For progressive renal cell carcinoma, the drug is in phase three trials with 280 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a phase three trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess test results and make decisions on approval.

Neovastat is being developed by Aeterna Laboratories of Quebec, Canada. For more information about current trials, call (888) 349-3232. If you are an oncologist, contact Claude Hariton, PhD, vice president of Clinical and Regulatory Affairs, (418) 652-8525, Ext. 306.

To learn more about anti-angiogenesis and Aeterna Laboratories, visit the Aeterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.

About The Author

Courtesy ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

Google

http://www.medmeet.com/
Internet Meetings | Medical Meetings On The Net | Take Your Meds | Kids Meet | Go Meetings

Take It Right   Medical Meetings On The Net   MD Meet